Compare ANIX & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIX | ATRA |
|---|---|---|
| Founded | 1982 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 94.2M |
| IPO Year | 2013 | 2014 |
| Metric | ANIX | ATRA |
|---|---|---|
| Price | $2.68 | $8.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $9.75 | ★ $13.67 |
| AVG Volume (30 Days) | ★ 306.6K | 36.6K |
| Earning Date | 09-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.82 | ★ 122.52 |
| EPS | ★ N/A | N/A |
| Revenue | $210,000.00 | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,334.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.32 | $3.92 |
| 52 Week High | $5.46 | $19.15 |
| Indicator | ANIX | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 39.55 | 49.17 |
| Support Level | $2.62 | $8.96 |
| Resistance Level | $3.09 | $9.64 |
| Average True Range (ATR) | 0.14 | 0.67 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 7.17 | 65.31 |
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.